Stocks Health care ACRS
NASDAQ · Health careAclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, Inc. brought in $6.4M of revenue over the twelve months to September 30, 2026, down 59.3% from a year earlier. It posted a net loss of $79.6M. In fiscal 2025 capital spending exceeded operating cash flow by $47.2M. At September 30, 2026 it held $20.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Aclaris Therapeutics, Inc.
- Net worth
- Aclaris Therapeutics, Inc. has a market value (market cap) of $624.1M at the latest share price, and shareholders' equity of $166.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $7.8M (-58.2% year on year), with a net loss of $64.9M. Over the 12 months to September 30, 2026: revenue $6.4M, net loss $79.6M.
- Cash flow
- In fiscal 2025 operations used $47.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Aclaris Therapeutics, Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Aclaris Therapeutics, Inc. does
Aclaris Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ACRS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $7.8M | -$64.9M | -$0.53 | -$47.2M |
| 2024 | $18.7M | -$132.1M | -$1.71 | -$20.2M |
| 2023 | $31.2M | -$88.5M | -$1.27 | -$79.6M |
| 2022 | $29.8M | -$86.9M | -$1.33 | -$68.2M |
| 2021 | $6.8M | -$90.9M | -$1.60 | -$52.4M |
| 2020 | $6.5M | -$51M | -$1.20 | -$39.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ACRS ranks in Health care
Latest SEC filings
What Aclaris Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 55% to $1.5M versus the same quarter last year; diluted EPS -$0.12 versus -$0.12.
- November 5, 2026
- October 27, 2026
- October 27, 2026
- September 21, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026
- August 6, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 8.3% to $1.6M versus the same quarter last year; diluted EPS -$0.15 versus -$0.13.
- August 6, 2026
Insider trades
What the people running Aclaris Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 1, 2026 | Kolbeck Roland WilhelmChief Scientific Officer | Exercised options | 36,375 | - |
| August 1, 2026 | Kolbeck Roland WilhelmChief Scientific Officer | Shares withheld for tax | 12,385 | $64.4K |
| June 5, 2026 | Schiff Andrew NDirector | Exercised options | 11,580 | - |
| June 5, 2026 | Milano VincentDirector | Exercised options | 11,580 | - |
| June 5, 2026 | Gowen MaxineDirector | Exercised options | 11,580 | - |
| June 5, 2026 | Mehra AnandDirector | Exercised options | 11,580 | - |
| June 5, 2026 | Molineaux Christopher P.Director | Exercised options | 11,580 | - |
| June 5, 2026 | Humphries William D.Director | Exercised options | 11,580 | - |
Who owns ACRS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| BML Investment Partners, L.P.13G, passive | 9.9% | April 27, 2026 |
| Biosion, Inc.13G, passive with 1 related filers | 9.4% | January 9, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 9.1% | August 14, 2026 |
| Deep Track Capital, LP13G, passive with 2 related filers | 7% | March 17, 2026 |
| Frazier Life Sciences Public Fund, L.P.13G, passive with 8 related filers | 5.4% | September 21, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 149 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| RA Capital Management, L.P. | 12,723,026 | +5,918,954 |
| BML Capital Management, LLC | 11,975,000 | -2,275,000 |
| BlackRock, Inc. | 10,037,008 | +2,629,943 |
| Deep Track Capital, LP | 9,345,000 | 0 |
| Vivo Capital, LLC | 6,694,637 | +27,971 |
| Vanguard Capital Management LLC | 5,817,866 | +650,397 |
| Frazier Life Sciences Management, L.P. | 4,925,374 | 0 |
| Rock Springs Capital Management LP | 4,330,532 | -142,118 |
| Adage Capital Partners GP, L.L.C. | 4,071,000 | +200,000 |
| Decheng Capital LLC | 4,041,736 | 0 |
| Kalehua Capital Management LLC | 3,664,730 | +494,809 |
| State Street Corp | 3,255,340 | +1,246,594 |
| Geode Capital Management, LLC | 3,190,058 | +766,367 |
| Braidwell LP | 2,142,348 | +443,232 |
| Balyasny Asset Management L.P. | 2,023,470 | -1,337,858 |
| Silverarc Capital Management, LLC | 1,946,482 | new |
| Citadel Advisors LLC | 1,762,081 | -487,238 |
| Jones Hill Capital LP | 1,759,492 | new |
| Palo Alto Investors LP | 1,613,430 | 0 |
| Woodline Partners LP | 1,611,054 | +125,431 |
Insiders
13 insiders reported holding 16,898,873 shares in total, about $71.7M at the last price.
| Holder | Shares |
|---|---|
| Leonard Braden Michael10% owner | 13,950,00013,950,000 held indirectly |
| Walker NealCEO, Director | 1,543,886 |
| Mehra AnandDirector | 726,403 |
| Loerop JamesChief Business Officer | 192,260 |
| Balthaser KevinChief Financial Officer | 187,453 |
| Molineaux Christopher P.Director | 69,536 |
| Davis Hugh M.President and COO, Director | 45,425 |
| Humphries William D.Director | 45,105 |
| Gowen MaxineDirector | 33,334 |
| Milano VincentDirector | 28,896 |
Questions about ACRS
What does Aclaris Therapeutics, Inc. do?
Aclaris Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as ACRS. Its shares trade on NASDAQ under the ticker ACRS.
What is Aclaris Therapeutics, Inc.'s net worth?
Aclaris Therapeutics, Inc. has a market value (market cap) of $624.1M at the latest share price, and shareholders' equity of $166.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Aclaris Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $79.6M on revenue of $6.4M.
How much revenue does Aclaris Therapeutics, Inc. make?
Over the twelve months to September 30, 2026 Aclaris Therapeutics, Inc. reported revenue of $6.4M. That is 59.3% less than a year earlier.
When did Aclaris Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Aclaris Therapeutics, Inc.'s next earnings report?
Aclaris Therapeutics, Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ACRS with
Follow ACRS
Get an email when Aclaris Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Aclaris Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.